SS18 and synovial sarcoma: Using ChIP-Seq, we observed regions where decitabine treatment led to the acquisition of new or increased binding sites for SS18::SSX and KDM2B in HS-SY-II human synovial sarcoma cells that did not correspond to previous KDM2B sites (Figure 7B).